Jamie is a highly-regarded equity analyst and fund manager. He began his career in investment management running the research process for equities for private clients and IHT portfolios. He moved over to portfolio management in 2013 and has managed hedge funds and long-only equity funds, including a seven-year stint as the manager of the then-highly-rated Oriel UK Fund. He then moved over to management when he became head of investments at a major investment platform. He now writes for publications and consults on equity investment throughout the UK.

Manolete Partners Plc is the UK’s leading insolvency litigation financing company, which was founded in 2009 by its Chief Executive, Steven Cooklin, a UK Chartered Accountant. 

Manolete finances the pursuit of UK insolvency claims through litigation and alternative dispute resolution to produce optimal returns for the creditors of insolvent companies and excellent returns for its shareholders, with investment IRRs above 100% over its 16-year history. The Company has invested in over 1,600 specialist UK insolvency cases, recovering over £165m, over an average case duration of just 14 months. It is renowned for its unparalleled knowledge of the Insolvency and Recovery sector.

Manolete works alongside Insolvency Practitioners from all the ‘Big Four’ through to one and two partner specialist insolvency and restructuring practices. Case values range from £20k to over £70m. Manolete was listed on the AIM Market of the London Stock Exchange in December 2018. HSBC provides the Company with a £17.5m revolving credit facility.  

Manolete has been voted Insolvency Litigation Funder of the Year on five occasions at the industry’s Turnaround, Recovery and Insolvency Awards. For five years in succession Manolete is the only firm to be ranked by Chambers in Band 1 for Litigation Funding: Insolvency.

Steven Cooklin, Chief Executive Officer, ACA ACSI CF

Steven founded Manolete in 2009 and is Chief Executive. Steven is a Chartered Accountant having qualified at PwC in 1991. Steven has over 20 years’ experience in corporate finance with National Westminster Bank, Calder Corporate Advisory Ltd and Hill Samuel Investment Bank and is a former director of HSBC Investment Bank (Corporate Finance Division). Steven is an Associate Member of The Association of Business Recovery Professionals.

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs. The Company's clinical programmes target large addressable markets including, cancer immunotherapy-induced Cytokine Release Syndrome ("CRS") and metabolic conditions such as obesity with the development of an oral encapsulated glucagon-like peptide GLP-1R agonist.

Jeremy Skillington, CEO

Jeremy Skillington, PhD began his biotechnology career in the Business Development group of Genentech, Inc in California in 2002. At Genentech he was responsible for executing over 40 licensing, investment and collaboration transactions. Returning to Ireland in 2009, Jeremy led Business Development and was a member of the Senior Management team at Opsona Therapeutics Ltd before becoming a founder and CEO of immuno-oncology company TriMod Therapeutics Ltd. In 2014 Jeremy joined German life science investment fund HS Lifesciences GmbH to provide start-up and business development support to portfolio companies ImmunoQure AG and Ethris GmbH. Jeremy joined Inflazome Ltd on its founding in 2016 and as VP of Business Development was instrumental in their acquisition by Roche in September 2020 for €380m upfront and significant downstream milestones for their portfolio of NLRP3 inflammasome inhibitors. He has been CEO of publicly listed Poolbeg Pharma Plc since June 2021.

Jeremy studied Biochemistry at the University of Galway, Ireland where he was awarded his PhD. He performed post-doctoral research at the University of California, San Francisco in the lab of Prof Rik Derynck. He is currently an Adjunct Assistant Professor at Trinity College, Dublin in the School of Biochemistry & Immunology.

Ian O’Connell, CFO

Ian O’Connell is an experienced financial professional with a depth of healthcare and public markets experience. In 2017 he co-founded Open Orphan plc, was made a Board Observer and as VP Corporate Development, he led the acquisition of hVIVO plc and the reverse takeover (RTO) of Venn Life Sciences plc. As a member of the core senior management team, Ian helped drive the company to its position today as a world leader in the testing of infectious and respiratory disease products using human challenge studies.

Prior to this, Ian worked closely with Cathal Friel and Amryt’s senior management on the establishment of Amryt Pharma plc. Ian gained Corporate Finance experience at both Raglan Capital and Deloitte Corporate Finance. Ian has a BSc (Hons) in Finance from University College Cork and is a Member of Chartered Accountants Ireland.

Investor Summit 2025 — Where insight meets action.

Join hundreds of other investors and industry experts for a full day of speakers, panels and purposeful networking. Whether you're focused on growth, governance or long-term value — you'll find fresh perspectives and meaningful connections here.

CLICK HERE FOR TICKETS

CYJAX is a leading cyber threat intelligence company that helps organisations detect, understand, and respond to digital threats before they impact business. Our intelligence-led platform fuses open-source, dark web, and technical threat data to provide real-time, contextual insights that drive smarter security decisions.

Serving global enterprises, governments, and financial institutions, CYJAX delivers tailored intelligence that strengthens threat detection, incident response, and strategic risk management. Our team of expert analysts and cutting-edge technology enables clients to stay ahead of emerging threats in an increasingly complex cyber landscape.

Trusted, agile, and innovation-driven, CYJAX empowers organisations to move from reactive defence to proactive resilience - reducing risk, enhancing situational awareness, and safeguarding critical assets.

Jonathan Bennett , CEO

Jonathan Bennett is the CEO of CYJAX, a leading threat intelligence company serving global enterprises and government clients. Jonathan brings over 20 years of leadership experience, with deep expertise in executing go-to-market strategies and scaling organisations. He has held senior leadership roles at Mastercard, DOCOMO Digital, and Travelex, as well as fast-growth fintech businesses delivering innovation, strategic growth, and high-performing teams.  Since taking the helm, he has driven CYJAX’s growth, product innovation, and market expansion. 

Aeorema Communications plc (AIM: AEO.L) is a leading strategic communications Group based in London, New York and Cannes. Through its agencies, Aeorema provides a suite of creative brand experience, strategic consultancy and event services to an international blue-chip client base, helping clients maximise and deliver on their long-term communication strategies over multiple event and film touchpoints.

The dividend-paying Group delivers these services via its fully owned Cheerful Twentyfirst companies, two live events agencies that specialise in devising and delivering corporate communication solutions across the globe. The Group also operates Eventful, which provides consultative, high-touch services including assisting clients with venue sourcing, event management and incentive travel. 

Steve Quah, CEO

Steve Quah is a founder and Chief Executive Director at Cheerful Twentyfirst and oversees the management of all events. With extensive expertise in both theatrical and digital brand experiences, Steve is the driving force behind the company’s strong creative service ethos. Steve brings over thirty years of unique insight, innovation and experience to the company and continues to focus the team on delivering game changing events for all clients. With a passion for creating award winning brand experiences, Steve has produced over 400 corporate productions and numerous live events for some of the world’s largest brands including Stagwell Group, Vodafone, Google, KPMG, Clifford Chance, LG, Disney, BBC, News UK and Microsoft to name but a few.

BASH is an acronym for Buy, Avoid, Sell and Hold a share in a company to be discussed during each panel.

Damian Cannon

Damian is an experienced private investor who has tried almost every successful strategy, and many that weren't, over the last 20 years. During that time, he has published deep-dive analysis of individual companies, blogged a monthly trading journal and established the StockSlam social investor event. He probably could have saved a lot of time by sticking with the Zulu Principle from the beginning but where's the fun in that?

Ildar Davletshin

Ildar Davletshin, CFA, is a former equity research analyst. He is currently focused on managing his own portfolio. He prefers two types of investments: quality businesses at a discounted price or severely undervalued stocks (‘deep value’). In addition to that, he publishes the Hidden Value Gems newsletter where he discusses some of his investment ideas. He has two children and lives in London, UK.